Sherbrooke Capital

Founding Managing General Partner John Giannuzzi leads the investment committee alongside Partner Mike Morelli. Giannuzzi started the firm in 1998, and the partnership structure remains concentrated, with operating partners supplementing deal sourcing and portfolio-company oversight rather than voting on investments.

Sherbrooke operates as a growth-equity and buyout hybrid, not a traditional venture capital firm. It targets companies with $5M to $30M in revenue, deploying growth capital, recapitalizations, and management buyouts. It will take control or significant minority stakes, which distinguishes it from seed-stage venture investors.

Sherbrooke principally makes direct investments in operating companies. The firm does not publicly indicate a significant fund-of-funds program. It co-invests alongside other GPs when deal size or geography warrants, but its primary posture is direct control and significant-minority investing.

Sherbrooke avoids biotech, pharmaceuticals, medical devices, and generalist consumer categories such as apparel and durable goods. The firm invests exclusively in branded health-and-wellness consumer goods, active-lifestyle products, and better-for-you food and beverages — a thesis that explicitly excludes FDA-regulated therapeutics and non-consumer-facing health services.

Sherbrooke co-invests opportunistically when deal size exceeds single-fund capacity or when a co-investor brings complementary sector expertise. Its primary default is leading control or significant-minority rounds alone or as the lead sponsor.